NCT06705023View on ClinicalTrials.gov

Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Myocardial InjuryLV DysfunctionCoronary Artery DiseaseHeart Failure
Interventions
BIOLOGICAL

Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)

Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.

OTHER

Continuation of patient's best guideline based medical treatment

Patients will receive continuation of their best guideline based medical treatment.

Trial Locations (1)

010009

RECRUITING

National Scientific Medical Center, Astana

All Listed Sponsors
collaborator

National Scientific Medical Center, Kazakhstan

OTHER_GOV

collaborator

Internationnal Foundation Medicine and Science

UNKNOWN

collaborator

Alliance of Cardiovascular Researchers

OTHER

lead

Ralf Rothoerl

OTHER